Phase II Study of RR110 in Patients With Active Crohn's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions

Crohn's Disease

Interventions

DRUG

RR110 (Tamibarotene)

1 mg RR110

DRUG

RR110 (Tamibarotene)

4 mg RR110

Trial Locations (8)

Toyohashi

Sakura

Sapporo

Nishinomiya

Fujisawa

Nakagami

Ōtsu

Shinjuku

All Listed Sponsors

lead

R&R Inc.

INDUSTRY

NCT00417391 - Phase II Study of RR110 in Patients With Active Crohn's Disease | Biotech Hunter | Biotech Hunter